NCT07204457: Immunogenicity and Safety of Meningococcal Conjugate Vaccine (EG-MCV4) in Healthy Adults Aged 19 to 55 Years Old
- State
- Under way
- Phase
- Phase 2 and Phase 3
- People
- 1,123 planned
- Started
- 15 Oct 2025
- Primary completion
- Sep 2026
- Arms
- EG-MCV4 (Test group 1), EG-MCV4 (Test group 2)
- Results
- None posted
- 2 Oct 2025: Trial registered
- 15 Oct 2025: Trial started